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Control of proper protein synthesis, function, and turnover is essential for the health
of all cells. In neurons these demands take on the additional importance of supporting
and regulating the highly dynamic connections between neurons that are necessary for
cognitive function, learning, and memory. Regulating multiple unique synaptic protein
environments within a single neuron while maintaining cell health requires the highly
regulated processes of ubiquitination and degradation of ubiquitinated proteins through
the proteasome. In this review, we examine the effects of dysregulated ubiquitination and
protein clearance on the handling of disease-associated proteins and neuronal health in
the most common neurodegenerative diseases.
Keywords: ubiquitin, neurodegenerative diseases, proteasome, protein quality control, Alzheimer’s disease,
Parkinson disease, Amyotrophic Lateral Sclerosis, Huntington’s disease
INTRODUCTION
The unique demands placed on neurons by their exquisitely
complicated and dynamic architecture have been appreciated by
investigators for over 100 years (Golgi, 1886; Ramon y Cajal,
1909; Herculano-Houzel, 2011). A recent study places the num-
ber of neurons in the human brain at approximately 85 billion
(Azevedo et al., 2009). With each neuron making upwards of
10 thousand synaptic connections, the estimated total number
of synapses reaches toward 8.5 hundred trillion (8.5 × 1014).
Astonishingly, plasticity can occur selectively at particular sub-
sets of synapses within a neuron, even down to the level of a
single specified synapse (Lee et al., 2010). Failure to maintain
these synaptic connections and their proper plasticity are hall-
marks of a host of neurodegenerative diseases, and loss of synaptic
connections correlates with diminished cognitive function even
before neurons degenerate (Masliah et al., 1991a,b). With 2788
unique proteins already identified as integral to the composition
of each synapse (Pielot et al., 2012), the management of unique
protein environments requires sufficiently complex and modifi-
able systems of protein quality control. The Ubiquitin Proteasome
System (UPS), a set of interacting enzymes and associated pro-
teins, is able to address these diverse proteostatic needs through
the orchestrated activity of over 500 components working in ver-
satile combinations to regulate protein-protein interactions and
eliminate unwanted proteins. As newly synthesized proteins form
new structures and connections, the UPS works to ensure that old
proteins are degraded to make way and that the proper comple-
ment of buildingmaterials is available. To achieve these functions,
components of the UPS are recruited to dendritic spines in
response to synaptic activity (Bingol and Schuman, 2006; Bingol
et al., 2010). Evidence continues tomount for the necessity of UPS
involvement in the dynamic remodeling of synaptic structures
following synaptic activity (Hegde et al., 1997; Ehlers, 2003; Pak
and Sheng, 2003; Patrick et al., 2003; Bingol and Schuman, 2004;
Hung et al., 2010; Fu et al., 2011). Many synaptic components
have been identified as activity-dependent substrates for agents of
the UPS. These include postsynaptic receptors (Kato et al., 2005;
Lussier et al., 2011) and the scaffolding proteins which hold them
in place (Colledge et al., 2003; Shin et al., 2012). Transsynaptic
proteins such as Beta-Catenin and Beta-Integrin align and con-
nect pre- and post-synaptic elements and are degraded through
the UPS (Yoshida et al., 2002; Dreier et al., 2005). The shape,
size, and placement of dendritic spines are also determined in
part by proteins that regulate cytoskeletal organization and are
themselves subject to ubiquitin-mediated degradation (Bingol
and Schuman, 2005; Marland et al., 2011). These contributions
to synapse maintenance and synaptic plasticity require that the
UPS functions properly. For example, pharmacologic inhibition
of the UPS leads to a frank reduction in activity-dependent synap-
tic plasticity (Ehlers, 2003) and a dose-dependent loss of synaptic
connections (Bajic et al., 2012). Robust loss of synaptic connec-
tions is evident in all of the major neurodegenerative disorders.
The full role of ubiquitination pertaining to synaptic structure
and function remains incompletely understood, but has been
the focus of significant investigation (Hegde and Upadhya, 2007;
Bingol and Sheng, 2011; Hanus and Schuman, 2013).
As important as the contributions of the UPS to maintaining
the plasticity of synapses are its diverse roles in ensuring general
cell health, including the elimination of misfolded or damaged
proteins, mediation of receptor signaling pathways, response to
DNA damage and oxidative stress, and progression of the cell
cycle, among other roles (Bernassola et al., 2010; Shang and
Taylor, 2011). UPS function is essential to cell health and sur-
vival in all cell types. Improper clearance of proteins is believed
to be a causative or contributing factor in many neurodegenera-
tive diseases, which are often characterized by the accumulation
of aggregated proteins (Alves-Rodrigues et al., 1998; Huang and
Figueiredo-Pereira, 2010). Whether aggregation itself is the cause
of toxicity or merely represents a strategy by which neurons
sequester toxic proteins remains contested (Ross and Poirier,
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2005), but the failure of quality control pathways to elimi-
nate these unwanted proteins is evident. UPS dysfunction has
been reported in the most common neurodegenerative diseases,
including Alzheimer’s disease (AD), Parkinson’s disease (PD),
Amyotrophic Lateral Sclerosis (ALS), and Huntington’s disease
(HD), as well as less common disorders and various animal mod-
els of protein aggregation (Keller et al., 2000; Bence et al., 2001;
McNaught et al., 2003; Seo et al., 2004; Lonskaya et al., 2013).
How the UPS becomes impaired in disease states is not always
clear, as too little is known about how disease-related proteins
are handled under normal conditions. Research into these areas
has begun to reveal just how intricate and extensive ubiquitin-
mediated processes within the cell are, and accordingly, just
how significant their dysregulation in a pathogenic context must
be. Recent studies describing the plurality of ubiquitin-related
abnormalities seen in disease states suggest the intriguing possi-
bility that the disruption of one such process leads into that of
another. Hopefully, further investigations will uncover potential
therapeutic interventions.
UBIQUITINATION AND THE UBIQUITIN PROTEASOME
SYSTEM
Ubiquitin is a 76 amino acid (∼8 kDa) protein expressed in all
eukaryotic cells. It is highly conserved throughout evolution; the
amino acid sequence of human ubiquitin is identical to that of
Aplysia (Hegde et al., 2000) and nearly identical to that of yeast
(Finley and Chau, 1991). Through the coordinated activity of
multiple enzymes, ubiquitin is covalently added to substrate pro-
teins through the formation of an iso-peptide bond between the
C-terminal diglycine motif of ubiquitin and lysine residues on
the target (Figure 1) (Hershko and Ciechanover, 1998). This cas-
cade begins with the ATP-dependent attachment of ubiquitin’s
C-terminal glycine through a thio-ester bond to an active-site
cysteine on an Ubiquitin Activating Enzyme (E1). This ubiq-
uitin is then transferred to a Ubiquitin Conjugating Enzyme
(E2) through a thio-ester bond. From there, the E2 enzyme will
cooperate with a Ubiquitin Ligase (E3) to transfer the ubiquitin
molecule to the target lysine on a substrate protein. This last step
occurs differently depending on the type of E3 involved, but it is
at this step that substrate specificity is believed to occur, with E3
ligases selecting substrates for ubiquitination. However, this view
has recently come under some scrutiny, as evidence emerges for a
role for E2s in the process of substrate selection (Scaglione et al.,
2013).
E3s are typically grouped into three classes, with each defined
by the specific protein domains it possesses. These domain-based
classes include: (1) Really Interesting New Gene (RING) finger-
containing E3s, (2) Homologous to E6-AP (HECT) domain-
containing E3s, and (3) E3s composed of multiple subunits.
RING finger-containing E3s bring the E2 and the substrate pro-
tein into sufficiently close proximity for the transfer of the ubiq-
uitin to its target lysine (Lorick et al., 1999). HECT-domain
containing proteins possess an active-site cysteine to which the
ubiquitin is first transferred from the E2 before being passed to
the substrate protein (Huibregtse et al., 1995). In contrast to these
single-unit E3 ligases, multi-subunit ligases are composed of mul-
tiple adaptor proteins, cofactors, and scaffolding proteins that
confer substrate specificity and facilitate ubiquitination (Cardozo
and Pagano, 2004). The Skp1/Cul1/F-box (SCF) protein complex
and the Anaphase-promoting Complex (APC) are among the best
studied of these multi-subunit E3s. SCF complexes can include
various combinations of scaffolding proteins called cullins, F-box
proteins, and substrate adaptors (Hao et al., 2005). APC is less
variable, containing Apc2, Apc11, and either Cdh1 or Cdc20 for
substrate recognition (Biggs et al., 2006). Each E3 can recognize
multiple substrates; Fbxw1/β-TRCP1, for example, has upwards
of 40 documented substrates itself (Skaar et al., 2009). Further
contributing to the complexity of these multi-subunit E3 ligases
is the developmental and spatial restriction of their expression
within cells (Pines, 2006). There are estimated to be at least
500 different E3 ligases, with more continuing to be discovered
(Ardley and Robinson, 2005).
This highly regulated process adds ubiquitin to target lysines
on the substrate, but it can also add other ubiquitin molecules
onto lysines of a ubiquitin already conjugated to a substrate. By
this process, ubiquitin chains of varying length and composi-
tion can be formed. The elongation of ubiquitin chains can occur
at any of ubiquitin’s own seven lysines, resulting in the forma-
tion of different linkage types (Peng et al., 2003). Although all
possible linkage types are present in cells, their precise functions
remain only partially understood (Xu et al., 2009). Chains formed
through the addition of ubiquitin exclusively at lysine 48 (K48)
have been recognized to signal protein degradation (Glickman
and Ciechanover, 2002), whereas K63-linked ubiquitin chains
seem to subserve diverse functions beyond protein degradation
(Jacobson et al., 2009). For example, K63-linked chains regu-
late NF-κB signaling not by promoting protein degradation but
by influencing ubiquitin-dependent protein-protein interactions
(Hadian et al., 2011). Elsewhere, however, they have been impli-
cated in promoting the lysosomal degradation of the low density
lipoprotein receptor (LDLR) (Zhang et al., 2013) and the epider-
mal growth factor receptor (EGFR) (Huang et al., 2013). Both
K48- and K63-linked chains have been observed to modify kinase
activity in response to cellular stress, as have K11-linked chains
(Ben-Neriah, 2002; Bertrand et al., 2011). K11-linked chains are
critical for cell-cycle regulation and cell division (Matsumoto
et al., 2010). Other linkages, including atypical, mixed-type link-
ages are less well studied, but have been implicated in similar
processes within the cell (Ikeda and Dikic, 2008; Husnjak and
Dikic, 2012).
The functions thus far attributed to specific chain link-
ages represent only a fraction of the diverse roles ubiquitin
is known to play in cellular processes (Husnjak and Dikic,
2012), many of which do not depend on proteasome function
(Mukhopadhyay and Riezman, 2007). Ubiquitination regulates
DNA repair (Jackson and Durocher, 2013), protein localiza-
tion and endocytosis (Haglund et al., 2003; Hicke and Dunn,
2003; Schnell and Hicke, 2003), and protein-protein interactions
(Hoege et al., 2002; Moldovan et al., 2007). Free, unanchored
chains of ubiquitin molecules are also present in cells and can reg-
ulate numerous functions including kinase activation (Xia et al.,
2009). The UPS has been also been implicated in the turnover
of mRNA, although whether this regulation is direct or indirect
remains unclear (Cano et al., 2010). Intriguingly, E3 ligases can
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FIGURE 1 | The process of ubiquitin conjugation. 1. Ubiquitin (U) is bound
via a thioester bond to the active-site cysteine of an E1 Ubiquitin-Activating
enzyme, through a process requiring ATP. 2. The ubiquitin molecule is then
passed to an E2 Ubiquitin-Conjugating Enzyme through
trans(thio)esterification. 3. An E3 ubiquitin ligase brings the E2 into
sufficiently close proximity and correct alignment with a substrate protein to
facilitate the transfer of ubiquitin to a target residue. In the case of HECT-type
E3s, the ubiquitin is first transferred to an active site cysteine on the E3
before being conjugated to the substrate. E3s can also exist as multi-subunit
complexes including scaffolding and adaptor proteins that confer substrate
specificity to the process of ubiquitin transfer. 4. Additional ubiquitin
molecules can be added onto the first to create polyubiquitin chains on
substrate proteins. 5. The 26S proteasome is composed of a cylindrical,
proteolytic 20S core which is capped at both ends by a 19S regulatory cap.
Polyubiquitinated substrate proteins, typically bearing K48-linked chains, are
targeted to the proteasome by trafficking proteins. The proteasome digests
these substrates into smaller peptides and free ubiquitin molecules, which
then can be used to modify further substrates.
themselves be targeted for ubiquitination, offering an additional
level of control for this important pathway (Buschmann et al.,
2000; Xiong et al., 2009). The ubiquitination of E3 ligases can
result either in their degradation or in the modification of their
activity (Scaglione et al., 2011).
Once a substrate is tagged for elimination through the addition
of a ubiquitin chain, it must be targeted to the cell’s degrada-
tion machinery by chaperone proteins that recognize and bind to
poly-ubiquitin chains. One such chaperone is Valosin-containing
protein (VCP), which has been shown to physically interact with
and shuttle poly-ubiquitinated substrates to the proteasome to
facilitate their degradation (Figure 1) (Dai and Li, 2001). The
proteasome contains a catalytic protein complex referred to as the
20S core (Lowe et al., 1995), which is capped at each end by a reg-
ulatory protein complex (19S) (Finley, 2009; Zhang et al., 2009).
It is responsible for breaking down substrate proteins into small
peptides (Hough et al., 1987; Hadari et al., 1992).
The ubiquitination of substrate proteins is a reversible pro-
cess. The removal of ubiquitin is carried out by De-ubiquitinating
Enzymes (DUBs). DUBs play two important roles, allowing for
the editing of existing chains (Wilkinson, 1997) and the removal
of ubiquitin chains altogether from a substrate. As the presence
of ubiquitin chains prevents substrates from entering the pro-
teasome due to spatial restrictions, DUBs play an essential role
in determining the rate of protein clearance in cells (Hershko
and Ciechanover, 1998; Wilkinson, 2009), and certain DUBs
including USP14 are known to associate directly with the19S
regulatory complex of the proteasome (Borodovsky et al., 2001).
It is important to consider that while numerous studies report
proteasome dysfunction in disease states, proteasomal degrada-
tion is only one of several potential outcomes of ubiquitination
that may contribute to pathogenesis when impaired. Indeed,
there are numerous examples of dysregulated protein handling
due to failures in ubiquitination that do not necessarily impli-
cate the proteasome. Whether the effects of proteasomal failure
reach upstream to impact the activity and efficacy of E1s, E2s,
or E3s is not clear. Given that K48-linked chains are among the
most common found in cells (Ziv et al., 2011), it is conceiv-
able that impaired proteolysis could deplete cellular pools of free
ubiquitin and thereby induce further dysfunction. Accordingly,
an imbalance in ubiquitination/deubiquitination activities may
result in improper chain formation, preventing the proteasome
from recognizing and handling targeted substrates. To examine
these two separate yet related phenomena, it will be helpful to
distinguish whether dysfunction occurs in UPS per se or, more
broadly in the Ubiquitin Signaling System (USS) which includes
the labeling of proteins with ubiquitin for any number of intended
outcomes beyond degradation. While impaired clearance charac-
terizes UPS failure, it remains to be seen whether and how the
other, non-proteasomal components of the USS contribute to dis-
ease processes. One example of this distinction is evident in the
ubiquitin-mediated fate of Caspase proteins.
Though the precise methods by which neurons degenerate
in disease remain unclear, substantial evidence supports a role
for proteases of the Caspase family. For example, activated cas-
pases are elevated in AD patient tissue (Bredesen, 2009). Upon
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activation, caspases can either activate other proteases (initiator
caspases) or damage essential components of the cell and pro-
mote apoptosis (effector caspases). Sublethal amounts of caspase
activation have been linked to synaptic dysfunction in an animal
model of AD (D’Amelio et al., 2011). Caspase-mediated effects
can be inhibited both by the inactivation of caspase enzyme activ-
ity and by their targeted degradation through the proteasome.
The X-linked Inhibitor of Apoptosis Protein (XIAP) and its fam-
ily member cIAP1 are RING-type E3 ligases that directly bind to
and target caspases for degradation; XIAP is also able to inhibit
the proteolytic activity of caspases (Suzuki et al., 2001; Choi et al.,
2009). The regulation of caspases by XIAP is limited, however,
in oxidative stress conditions. Both acute and chronic inflamma-
tion, which are often associated with disease, elevate the levels of
nitric oxide in neurons. This elevation can lead to the aberrant
addition of nitric oxide to proteins (nitrosylation). Dysregulated
nitrosylation of proteins is evident in several neurodegenerative
diseases, including AD (Nakamura et al., 2013). The addition
of nitric oxide (nitrosylation) to the active cysteine of XIAP’s
RING domain inactivates its E3 ligase activity. Nitrosylated XIAP
is unable to ubiquitinate caspases and thus unable to inhibit apop-
tosis (Nakamura et al., 2010). The relative amount of nitrosylated
XIAP is increased in AD patient tissue, suggesting a role in the
accelerated apoptosis observed in disease (Nakamura et al., 2010).
Here, then, is one example in which the state of the proteasome
in disease is secondary to the decreased ability of E3 ligases to tar-
get caspases for degradation. Therefore, it is essential to consider
how disease-related proteins are modified by agents of the USS
while also examining whether affected neurons can execute the
intended consequences of that modification.
UBIQUITINATION IN NEUROPATHOLOGY
To further illustrate the complexity and fundamental significance
of ubiquitin-mediated pathway involvement, we review key find-
ings about the handling of disease-related proteins by the USS and
UPS in several of the most common neurodegenerative diseases.
ALZHEIMER’S DISEASE
Alzheimer’s disease is the most common form of dementia and
the most common neurodegenerative disorder. Its symptoms
include a progressive decline inmemory and other cognitive func-
tions. Histologically, AD involves extensive neurodegeneration
and loss of synaptic connections, resulting in progressive atrophy
of the temporal, frontal and parietal lobes of the cerebral cortex.
It is characterized by the hallmark deposition of intracellular, fil-
amentous aggregates mainly consisting of hyper-phosphorylated
Tau (neurofibrillary tangles, NFTs) and extracellular plaques
rich in Amyloid-Beta (amyloid plaques) (Glenner et al., 1984;
Goedert et al., 1988; Wischik et al., 1988). Ubiquitinated forms
of Tau and Amyloid-Beta, as well as other ubiquitinated proteins,
are major components of these aggregates (Perry et al., 1987).
Amyloid-Beta, produced by the cleavage of the Amyloid Precursor
Protein (APP), is thought to have numerous deleterious effects on
neuronal health and connectivity (Thinakaran and Koo, 2008).
Mutations in the genes encoding APP or the presenilin protease
enzymes that cleave APP to generate Amyloid-Beta cause early-
onset AD, and support the notion that Amyloid-Beta metabolism
is a central component of AD pathogenesis (Bertram et al., 2010).
The generation of hyper-phosphorylated Tau is less clearly under-
stood. It has been suggested that Amyloid-Beta is able to stimulate
the kinase GSK3-B, resulting in the aberrant phosphorylation of
Tau (Hernandez et al., 2010). The mechanisms governing the
synthesis, processing, and degradation of these proteins remain
incompletely understood. Inhibition of the proteasome causes an
increase in Amyloid-Beta (Kumar et al., 2007), and numerous
studies have begun to describe an extensive role for both ubiq-
uitination and the proteasome in the production and handling of
APP, Amyloid-Beta, and Tau (Figure 2).
APP is produced in the endoplasmic reticulum (ER). HRD1,
an E3 ligase associated with the clearance of newly synthesized
proteins through ER-associated degradation (ERAD), has been
shown to interact with APP. Decreasing HRD1 expression evokes
ER stress and apoptosis, accompanied by the accumulation of
APP and Amyloid Beta. The disease relevance of the HRD1/APP
relationship is supported by the reduced levels of HRD1 in AD
brain tissue (Kaneko et al., 2010). Similarly, the levels of Fbxo2, a
brain-enriched E3 ligase substrate adaptor protein also implicated
in ERAD, have been reported to be decreased in AD patient tissues
(Gong et al., 2010). Fbxo2 was also found to facilitate the degra-
dation of APP, and a knockout mouse model for Fbxo2 revealed
elevated levels of APP and Amyloid Beta in a brain region-specific
manner (Atkin et al., 2014).
In the Golgi apparatus, APP is ubiquitinated by unknown E3
ligases stimulated by ubiquilin-1, a protein with chaperone-like
properties. This ubiquitination is K63-linked and does not cause
the degradation of APP. Instead, it causes the retention of APP in
the early secretory pathway, impairing its maturation and delay-
ing its subsequent processing by secretases into Amyloid Beta (El
Ayadi et al., 2012). The process by which this ubiquitination of
APP is normally removed to allow processing remains unclear.
Ubiquilin-1 levels are significantly decreased in AD patient brain
tissues, further suggesting a role in AD pathogenesis (El Ayadi
et al., 2012). Single-nucleotide polymorphisms (SNPs) in the
UBQLN1 gene have recently been linked to late-onset AD (Stieren
et al., 2011).
After being produced and trafficked to the surface, APP
is internalized via endocytosis into the endosome and trans-
Golgi network and sequentially cleaved to produce Amyloid-
Beta (Thinakaran and Koo, 2008). The C-terminus of HSP70
Interacting Protein (CHIP) is an E3 ligase previously associated
with polyglutamine neurodegenerative disorders (Miller et al.,
2005; Williams et al., 2009). In ADmodels, CHIP has been shown
to interact with Amyloid-Beta in the Golgi, in a manner that
increases upon inhibition of the proteasome. Over-expression
of CHIP results in a decrease in Amyloid-Beta levels and may
stabilize levels of APP (Kumar et al., 2007).
Beyond targeting APP or Amyloid-Beta directly, the USS
affects numerous other components of the Amyloid pathway,
including the secretase enzymes responsible for the production
of Amyloid Beta. FBXW7 (SEL-10) facilitates the ubiquitination
of the gamma-secretase component Presenilin 1 (PS1), although
this ubiquitination unexpectedly increases Amyloid Beta produc-
tion through mechanisms that remain unclear (Li et al., 2002).
Fbxo2, described above, has also been implicated in the turnover
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FIGURE 2 | Regulation of protein trafficking, receptor signaling, and
protein clearance by ubiquitination in Alzheimer’s disease. Improper
processing of APP and Tau contribute to the pathology of AD. Excessive
or improperly folded APP is cleared from the ER by HDR1 and Fbxo2
through the addition of K-48 linked chains. Ubiquitin-mediated processes
are indicated by dashed lines. Maturation of APP is arrested in the early
secretory pathway by non-degradative, K-63 linked ubiquitination that is
stimulated by Ubiquilin 1. Surface APP is endocytosed to the late Golgi,
where it is cleaved by secretases including BACE-1 and PS-1, whose
levels are regulated by the E3 ligases Fbxo2 and FBXW-7, respectively.
The cleavage of APP results in the production of Amyloid-Beta, which
can be targeted for degradation by CHIP. Uncleared Amyloid-Beta is
exocytosed to the extracellular space, where it aggregates to form
plaques. Amyloid-Beta can influence NMDA receptor signaling. NMDA
receptor activation stimulates the kinase Cdk5, which results in the
downstream inhibition of the E3 ligase APC and blocks the degradation
of cyclin B1. NMDA receptor signaling also increases the activation of
GSK3B, which phosphorylates Tau. GSK3B is targeted for degradation by
NUB1, which also blocks the interaction between GSK3B and Tau.
GSK3B activity is increased by complexing with p53, whose levels are
regulated by the E3 ligase MDM2. Under conditions of cellular stress,
MDM2 auto-ubiquitinates and targets itself for degradation. The E3 ligase
CHIP targets Tau, but can have divergent effects on its handling. When
working in combination with Hsp70, CHIP targets Tau for degradation.
However, when Hsp90 is involved, CHIP facilitates an alternative
ubiquitination of unknown linkage type, resulting in the accumulation of
phosphorylated tau. Through an unknown mechanism, this accumulated
Tau then forms insoluble protein aggregates.
of the Beta-secretase protein BACE1 (Gong et al., 2010). Similarly,
overexpression of the E3 ligase Parkin, described below for its role
in PD, has been shown to reduce APP expression, Amyloid-Beta
burden, and inflammation while also restoring the formation of
long-term hippocampal synaptic potentiation in an AD mouse
model (Hong et al., 2014).
The effects of Amyloid-Beta on neurons are numerous, and
can also influenced by the complex actions of the USS in more
indirect methods than just the degradation of the Amyloid-
Beta peptide or its precursor. For example, exposure to excess
Amyloid-Beta causes diminished Brain-Derived Neurotrophic
Factor (BDNF) signaling in AD patient tissue and mouse mod-
els (Peng et al., 2005); however, this diminution can be reversed
by the overexpression of the de-ubiquitinating enzyme UCHL-1,
which, through an unknown mechanism, restores the traffick-
ing of BDNF receptors (Poon et al., 2013). Intriguingly, UCHL-1
levels are decreased in AD patient brains (Poon et al., 2013).
As another example, the intracellular response to Amyloid-
Beta is thought to be mediated through numerous proteins
including GSK3B, a kinase that is reportedly increased in AD and
has Tau as one of its substrates. GSK3B has been investigated as a
possible link between the two characteristic protein pathologies
of AD (Hernandez et al., 2010). The kinase activity of GSK3B
is enhanced by forming a complex with the tumor suppressor
protein p53. Under normal conditions, this interaction is lim-
ited by the degradation of p53 by the E3 ligase Mouse double
minute 2 homolog (MDM2). Under conditions of cellular stress,
however, MDM2 levels are decreased, leading to the increased
association of GSK3B and p53. This enhancement is thought
to contribute to the hyperphosphorylation of Tau seen in AD
(Proctor and Gray, 2010). The observed decrease inMDM2 under
conditions of stress actually stems from its own governance by
the UPS. Under normal conditions, MDM2 is modified by the
small, ubiquitin-like modifier protein SUMO. Sumoylation of
MDM2 prevents its auto-ubiquitination. Under conditions of cel-
lular stress, sumoylation of MDM2 is diminished, causing it to
become auto-ubiquitinated which then triggers its own degra-
dation by the proteasome (Buschmann et al., 2000). The level
of GSK3B in neurons is also mediated by yet another E3-ligase,
Nedd8 ultimate buster 1 (NUB1). NUB1 directly binds to GSK3B
and promotes its degradation by the proteasome, while also
inhibiting the interaction betweenGSK3B and Tau. NUB1 activity
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thereby diminishes the levels of hyper-phosphorylated Tau and
Tau aggregates (Richet et al., 2012).
NUB1 was originally identified for its role in regulating Nedd8
(Kamitani et al., 2001; Kito et al., 2001). Nedd8 is a small signaling
protein similar to ubiquitin both in structure (approximately 60%
identity and 80% homology to human ubiquitin) and in function
(Kumar et al., 1993; Kamitani et al., 2001). The conjugation of
Nedd 8, “neddylation,” to cullin proteins promotes the ubiquiti-
nation activity of SCF complexes (Duda et al., 2008). Nedd8 also
modifies other proteins, including transmembrane proteins such
as APP, and may influence their degradation (Chen et al., 2012).
Dysregulated clearance of Neddylated proteins in disease states is
evinced by the accumulation of Nedd8 in ubiquitin-positive tau
filamentous inclusions in some cases of AD and in Lewy bodies in
PD (Dil Kuazi et al., 2003).
CHIP, described above for its role in the turnover of
Amyloid-Beta, has also been shown to play a role in regulating
phosphorylated Tau. Through its interaction with two
heat-shock-induced proteins, Hsp70 and Hsp90, CHIP is able
to ubiquitinate phosphorylated Tau. Under normal conditions,
this ubiquitination leads to an accumulation of ubiquitinated
tau, which then becomes aggregated into high molecular-weight,
detergent-insoluble aggregates. CHIP immunoreactivity deco-
rates NFTs in several tauopathies, including AD (Petrucelli et al.,
2004). However, over-expression of Hsp70 shifts the handling
of ubiquitinated Tau toward a pathway of clearance through the
UPS, rather than aggregation, and reduces Tau levels in vitro
(Petrucelli et al., 2004). Intriguingly, in vitro the ubiquitination
of Tau also is carried out in an E3-ligase independent manner
by the E2 Ube2w (Scaglione et al., 2013). Ube2w, whose levels
are increased under cellular stress, also ubiquitinates CHIP and
regulates its activity (Scaglione et al., 2011). Additionally, a role
for CHIP in the ubiquitin-mediated turnover of caspases has
been described. Mice that lack CHIP show increased levels of
cleaved and uncleaved caspase-3 (Dickey et al., 2006).
Although not considered causative themselves, additional pro-
teins have been shown to exacerbate disease pathogenesis, and
are similarly subject to regulation by ubiquitination. NMDA
receptors are ionotropic glutamate receptors whose regulated
conductance of calcium into postsynaptic sites has been linked to
learning and memory. Aberrant activation and signaling of these
receptors has been implicated in numerous disease processes,
including AD (Hardingham and Bading, 2010). It has been sug-
gested that the Amyloid-Beta-induced loss of synapses requires
the activation of extra-synaptic NMDA receptors containing the
GluN2B subunit (Shankar et al., 2007; Talantova et al., 2013),
underscoring the importance of regulating NMDA receptor lev-
els and localization in AD pathology. GluN2B is ubiquitinated in
response to synaptic activity by the E3 ligase Mind Bomb-2 (Jurd
et al., 2008). Fbxo2, described above for its regulation of APP, also
regulates the levels of NMDA receptors in vitro by facilitating the
activity-dependent ubiquitination and elimination of the NMDA
receptor subunit GluN1 (Kato et al., 2005).
The downstream effects of NMDA receptor activation on cell
health include the regulation of ubiquitin-dependent pathways.
In one example, following NMDA receptor activation, the cyclin-
dependent kinase 5 (Cdk5) phosphorylates Cdh1, a key regulator
of the E3 ligase complex APC; in doing so, the turnover of its
cyclin B1 by APC is inhibited, promoting neurotoxicity following
NMDA receptor activation (Maestre et al., 2008).
PARKINSON’S DISEASE
Parkinson’s disease is the second most common neurodegener-
ative disease and the most common neurodegenerative move-
ment disorder. It is characterized by progressive abnormalities
in gait and posture, as well as difficulty initiating and complet-
ing voluntary and involuntary movements. Histopathologically,
PD involves the loss of dopaminergic neurons of the substan-
tia nigra and locus ceruleus accompanied by astrocytosis and
increased numbers of microglia. Throughout the brainstem of PD
patients, proteinaceous intracellular aggregates called Lewy bod-
ies can be found, comprised primarily of alpha-synuclein. With
slightly altered appearance, these synuclein-containing aggregates
can be seen in other brain regions, and the question of their con-
tribution to disease pathogenesis remains an area of intense study
(Syme et al., 2002). Although the majority of PD cases are of spo-
radic origin, the small fraction of inherited cases has provided
valuable insight into the role of the USS and UPS in PD pathology
(Figure 3).
Mutations in alpha-synuclein have been described in cases of
familial PD (Kruger et al., 1998; Riess et al., 1998), and the protea-
some is at least partially responsible for the turnover of this pro-
tein (Shimura et al., 2001). Proteasome dysfunction is reported in
the substantia nigra in PD, and proteasomal inhibition itself can
cause the formation of protein inclusions and eventual degenera-
tion of neurons in the substantia nigra in rats, although with some
inconsistency (McNaught and Jenner, 2001; McNaught et al.,
2002; McNaught and Olanow, 2006). The expression of mutant
alpha-synuclein induces the formation of filaments which inter-
act directly with the 20S core of the proteasome and decrease its
proteolytic activity (Lindersson et al., 2004). This deficit in pro-
teasome function is ameliorated by the concomitant expression of
the E3 ligase Parkin (Petrucelli et al., 2002).
Of patients with inherited PD, nearly 40 percent of those with
an early onset of symptoms have mutations in the gene encoding
Parkin (Lucking et al., 2000). First described in Japan, multiple
mutations in Parkin have now been described in one or both
alleles (Khan et al., 2003). While mutations in alpha-synuclein
cause autosomal dominant PD, mutations in Parkin cause auto-
somal recessive PD. These mutations result in the loss of Parkin
function, one aspect of which is to regulate the ubiquitination
of alpha-synuclein. Because the accumulation of ubiquitinated
alpha-synuclein is evident in both familial and sporadic PD,
Parkin dysfunction may also play a role in idiopathic PD and the
formation of Lewy bodies (Shimura et al., 2000; Hardy, 2003).
Consistent with this view, targeted expression of mutant Parkin
in disease-related brain regions of animal models yields similar
pathologies to those observed in PD (Lu et al., 2009).
Parkin is also involved in the intricate regulation of pro-
survival signaling through the Akt pathway by Epidermal Growth
Factor (EGF) (Fallon et al., 2006). EGF-Akt signaling occurs
through EGFRs which are decreased in disease-related brain
regions of patients with PD (Iwakura et al., 2005). Accordingly,
increased activation of EGFR in an animal model of PD prevents
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FIGURE 3 | Ubiquitination in pro-survival pathways, mitochondria
stability, and protein clearance in Parkinson’s disease. Dysregulation of
Parkin and UCHL1, both of which are associated with PD, has widespread
effects on neuronal health. The Epidermal Growth Factor (EGF) binds to
EGFR and initiates pro-survival signaling through the Akt and mTOR
pathways. Ligand-binding to EGFR stimulates its ubiquitination, which allows
for its UIM-dependent recognition by Eps15. Eps15 internalizes EGFR,
allowing it to be trafficked to the proteasome for degradation. The
EGFR-Eps15 interaction is blocked by the interaction of the UBL of the E3
ligase Parkin with the UIM of Eps15; this interaction increases Parkin’s ligase
activity, causing Eps15 to become ubiquitinated and dissociated from its
UIM-dependent interactors. Downstream of EGFR signaling, mTOR’s
participation in the protein complex mTORC1 requires the ubiquitination of
Raptor by DDB1 and Cul4. This ubiquitination is undone by the
de-ubiquitinating enzyme UCHL1. Parkin also plays a role in the degradation
of mitochondrial outer membrane proteins including Tom20, and through its
involvement with PINK1 and Dj-1, facilitates the degradation of Synphilin-1
and itself. Synphilin interacts with alpha-synuclein, which can be degraded by
Parkin in association with CHIP. Dimerized UCHL1 may also modify
alpha-synuclein, though the result is non-degradative, K-63 linked
ubiquitination which promotes its accumulation. Accumulated alpha-synuclein
binds to the 20S core of the proteasome and inhibits proteasome function.
the loss of dopaminergic neurons (Iwakura et al., 2005). EGF sig-
naling is regulated by ubiquitin in several ways. Ligand binding of
EGFR stimulates Akt signaling, but triggers the endocytosis and
degradation of EGFR, thereby limiting the extent of EGF signal-
ing. This process is mediated by the activity-dependent ubiquiti-
nation of EGFR by an unknown E3 ligase, which makes it eligible
for recognition by the ubiquitin-interacting motif (UIM) of the
EGFR Protein tyrosine kinase Substrate #15, Eps15. Interaction
with Eps15 is necessary for the internalization of EGFR, as Eps15
links ubiquitinated EGFRs to the machinery which traffics them
to the proteasome for degradation (van Bergen En Henegouwen,
2009). Parkin, which contains an amino-terminal ubiquitin-like
(UBL) domain, blocks the Eps15-EGFR interaction by bind-
ing to the UIM of Eps15 through this UBL domain, and then
facilitating the ubiquitination of Eps15. In this manner, EGFR
internalization is prevented, and EGF signaling and activation
of pro-survival pathways are enhanced. But interaction between
Eps-15 and Parkin suggests yet a further level of ubiquitin-
dependent regulation. Eps-15 promotes its own ubiquitination
by stimulating Parkin’s E3 ligase activity upon interaction. This
ubiquitination, which is believed to be K63-linked, prevents the
interaction of ubiquitinated Eps15 with other ubiquitinated pro-
teins such as EGFR and Parkin itself. Notably, Parkin deficiency
causes a reduction in EGF signaling (Fallon et al., 2006). Here,
again, dysfunctional ubiquitin signaling, independent of protea-
somal cleavage, is able to regulate the health of neurons in a
disease context.
Parkin has been shown to function as part of a macromolec-
ular E3 ligase complex which includes the pten-induced kinase
(PINK1) and the peptidase Dj-1 (Xiong et al., 2009). Mutations
in both PINK1 and Dj-1 cause hereditary PD (Abou-Sleiman
et al., 2003; Valente et al., 2004). Together, these proteins facil-
itate the degradation of Parkin substrates. Synphillin-1, which
interacts with alpha-synuclein and is also present in Lewy bod-
ies, is one such substrate, as is Parkin itself (Xiong et al., 2009).
Additionally, the interaction between PINK1 and Parkin facili-
tates the degradation and turnover ofmitochondria (Greene et al.,
2003; Vincow et al., 2013). In order to do so, Parkin targets
proteins in the outer mitochondrial membrane for degradation,
including Tom20 (Yoshii et al., 2011). These findings suggest
that Parkin dysfunction may contribute to global cellular health
problems, even beyond the accumulation of alpha-synuclein and
synphillin-1.
Rare mutations associated with familial, early-onset PD are
also found in the de-ubiquitinating enzyme UCH-L1, described
above for its role in AD (Das et al., 2006). These disease-associated
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mutations reduce the DUB activity of UCHL1. UCH-L1’s role
is significant for the health and function of neurons through
its regulation of substrates involved in governing mRNA tran-
scription, protein translation, synaptic plasticity, and pro-survival
signaling. These processes are potently influenced by the activ-
ity of a serine/threonine protein kinase originally identified for
its susceptibility to inhibition by Rapamycin, the Mammalian
Target of Rapamycin, mTOR (Sabatini et al., 1994; Hay and
Sonenberg, 2004; Ghosh et al., 2008; Hoeffer and Klann, 2010).
Intriguingly, mTOR function requires both the correct ubiqui-
tination of interacting proteins and proteasome activity (Ghosh
et al., 2008; Quy et al., 2013). mTOR asserts its effects through
the formation of large protein complexes. mTOR can function
in combination with Raptor (mTOR Complex 1 or mTORC1)
or Rictor (mTORC2). mTORC1 regulates transcription and is
important for local protein synthesis, a necessary component
of several types of synaptic plasticity. mTORC2, on the other
hand, influences Akt signaling, cytoskeletal dynamics, and actin
polymerization (Costa-Mattioli and Monteggia, 2013). The bal-
ance between mTORC1 and mTORC2 formation depends on
the interaction of Raptor with a multi-subunit E3 ligase com-
posed of DNA Damage-Binding Protein (DDB1), Cullin 4A
(CUL4), and the RING-type E3 ligase RING box 1 (RBX1)
(Ghosh et al., 2008). Although the exact mechanism is still
unclear, the DDB1-CUL4 complex appears to ubiquitinate Raptor
in a manner that facilitates its incorporation into the mTORC1
complex including DDB1, CUL4, Raptor, and mTOR (Ghosh
et al., 2008). UCHL1 deubiquitinates Raptor, thereby destabi-
lizing mTORC1 complex formation and shifting the balance
toward mTORC2-dependent signaling (Hussain et al., 2013).
This shift may have a significant impact on the ability of neu-
rons to modify their synaptic content to promote learning and
memory, and may also represent a neuroprotective response
mechanism.
The loss of UCHL1’s DUB activity results in an accumu-
lation of alpha-synuclein at presynaptic terminals rather than
increased clearance (Cartier et al., 2012). Surprisingly, UCH-L1
had been proposed to act as an E3 ligase when it self-dimerizes;
this new activity is independent of the state of UCHL1’s DUB
activity (Liu et al., 2002). Acting as an E3 ligase, UCHL1 causes
the K63-linked ubiquitination of alpha-synuclein, which, in turn,
worsens PD pathology (Liu et al., 2002). Accordingly, a mutant
form of UCH-L1 with decreased E3 ligase activity upon dimer-
ization, but normal DUB activity, decreases PD pathogenesis (Liu
et al., 2002). The consequences of UCHL1’s ubiquitination of
alpha-synuclein remain unclear.
There have been several ubiquitin-linked proteins whose
involvement in neurotoxicity overlaps between AD and PD.
Of those described above, CHIP, MDM2, and HRD1 support
the importance of the UPS in pathological mechanisms in
multiple disease states. CHIP also interacts with Parkin and
stimulates its ligase activity (Imai et al., 2002). Even without
additional insult, the down-regulation of MDM2 is toxic to
dopaminergic neurons (Nair et al., 2006). And HRD1 levels are
increased in dopaminergic neurons under conditions of neu-
rotoxicity, suggesting a role in the response to cellular stress
(Mei and Niu, 2010).
AMYOTROPHIC LATERAL SCLEROSIS
Amyotrophic Lateral Sclerosis (ALS) is the most common fatal
neurodegenerative disease affecting motor neurons. The loss of
motor neurons in the brain and spinal cord of ALS patients
typically results in progressive paralysis and death within a few
years of onset. Non-motor pathologies, particularly cognitive
deficits, can also accompany motor deficits. Histopathologically,
ubiquitin-rich cytoplasmic inclusions appear in the remaining
motor neurons of ALS patients, accompanied by marked glio-
sis. Ubiquitin-positive inclusions can also be observed in cortical
brain regions, consistent with the observed cognitive decline in
many ALS patients (Lowe, 1994; Walling, 1999). Sporadic ALS
(SALS) represents greater than 90 percent of all ALS cases, with
familial ALS (FALS) accounting for the remaining <10 percent.
The etiology of ALS remains unclear, and what is known to date
has been determined largely through the study of genes origi-
nally identified asmutated in FALS. Importantly, the disease genes
that cause FALS are also found mutated in some SALS cases, and
the histopathologies of familial and sporadic cases are essentially
indistinguishable (Andersen and Al-Chalabi, 2011), suggesting
that studies of FALS will offer useful insight into all forms of ALS.
Among the disease genes associated with FALS, mutations in the
gene encoding Superoxide Dismutase 1 (SOD1) were described
first (Rosen et al., 1993), and mutations in the Transactivation
Response DNA-binding protein 43 (TDP-43) are among the most
common (Gitcho et al., 2008). Recently, genome-wide associa-
tion studies revealed a large hexanucleotide expansion—upwards
of 1600 repeats—within the non-coding region of the C9ORF72
gene to be causative in a Finnish cohort (Laaksovirta et al., 2010).
Numerous other studies have now observed this expansion in
20–50 percent of FALS cases, making it the most common cause
(Boeve et al., 2012; Chio et al., 2012; Simon-Sanchez et al., 2012).
The protein products of these genes accumulate in ubiquitin-
positive inclusions in disease-related neuronal populations, and
the mechanisms of their turnover and clearance provide insight
into the importance of the UPS in ALS (Figure 4).
SOD1 plays an important role in the elimination of free super-
oxide radicals. Its expression is regulated by several agents of
the UPS. The canonical HECT-type E3 ligase E6-AP directly
binds to and ubiquitinates SOD1 (Mishra et al., 2013). Levels
of E6-AP are decreased prior to the onset of neurodegeneration
in a mouse model of ALS expressing mutant SOD1, and over-
expression of E6-AP reduces the aggregation of mutant SOD1
in vitro (Mishra et al., 2013). NEDL1, a homolog of E6-AP,
is reported to selectively bind to mutant SOD1 but not wild-
type SOD1, facilitating its ubiquitination and clearance (Miyazaki
et al., 2004). NEDL1 is thought to function in concert with the
endoplasmic reticulum translocon-associated protein TRAP-δ,
suggesting a role for NEDL1in the ERAD of mutant SOD1 (Kunst
et al., 1997). The interaction between NEDL1 and mutant SOD1
increases with disease severity, and NEDL1 immunoreactivity
is observed in SOD1-positive inclusions in human spinal cord
tissue from FALS patients (Miyazaki et al., 2004). Also report-
edly present in SOD1-positive inclusions is the RING-finger type
E3 ligase Dorfin, which shares NEDL1’s selectivity in ubiqui-
tinating mutant, but not wild-type, SOD1 (Niwa et al., 2002).
Over-Expression of Dorfin in a mouse model of FALS reduces
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FIGURE 4 | A role for ubiquitination in the pathogenesis of Amyotrophic
Lateral Sclerosis. Impaired turnover of SOD1 and TPD-43 are implicated in
the etiology of ALS. Mutated or excess SOD1 in the ER is targeted for
degradation by the E3 ligase NEDL1 via the translocon protein TRAP. SOD1 in
the cytosol is targeted by the canonical HECT-type E3 ligase, E6-AP, and the
RING-type E3 Dorfin. TDP-43 can be ubiquitinated by Parkin in association
with HDAC6. This modification can include both K48 and K63-linked chains
and does not lead to the degradation of TDP-43, instead increasing the
proportion of TDP-43 in the cytosol. In the nucleus, TDP-43 regulates the
transcription of genes including Parkin. In the cytosol, accumulated TDP-43
can inhibit the proteasome and form protein aggregates. In cases associated
with mutations in the C9ORF72 gene, aggregates of DPR proteins are
present with ubiquitin- and p62-positive immunoreactivity, but do no
colocalize with TPD-43.
expression and aggregation of SOD1 while also diminishing
motor neuron degeneration (Sone et al., 2010).
The protein TDP-43, extensively aggregated in many in ALS
cases, normally has a predominantly nuclear localization. It
has two RNA binding domains and has been implicated in
RNA splicing and trafficking (Buratti and Baralle, 2001, 2010).
Ubiquitinated TDP-43 is a major component of cytoplasmic
inclusions in ALS (Neumann et al., 2006). Mutations associated
with ALS result in the redistribution of TDP-43 from the nucleus
to the cytoplasm (Igaz et al., 2011), although the precise mecha-
nisms by which TDP-43 contributes to ALS pathogenesis remain
the subject of intensive study (Janssens and Van Broeckhoven,
2013). TDP-43 expression inhibits proteasome function and
increases levels of ParkinmRNA and protein (Hebron et al., 2013)
by binding to ParkinmRNA (Polymenidou et al., 2011). Parkin, in
turn, is able to mediate both K48 and K63-linked ubiquitination
of TDP-43, though this modification does not cause a reduction
in the levels of TDP-43 (Hebron et al., 2013). TDP-43 is unlike
other substrates of Parkin-dependent K63-linked ubiquitination,
which are targeted for degradation through the autophagic path-
way (Olzmann and Chin, 2008). The interaction between TDP-43
and Parkin requires the histone deacetylase protein HDAC6 and
promotes the translocation of TDP-43 from the nucleus to the
cytoplasm (Hebron et al., 2013).
In C9ORF72-related ALS cases, TDP-43 is similarly present
in ubiquitin-positive, cytoplasmic aggregates (Mackenzie et al.,
2014). However, a second ubiquitin-positive pathology is also
observed: ubiquitin- and p62-positive inclusions that are TDP-43
negative, but stain positive for dipeptide products of abnor-
mal transcripts from the hexanucleotide repeats in C9ORF72
(Mackenzie et al., 2014). These dipeptide-repeat (DPR) prod-
ucts are made by unconventional, repeat-associated, non-ATG
initiated (RAN) translation of transcripts containing the hex-
anucleotide repeat expansion (Ash et al., 2013). The pathogenic
contribution of these dipeptide products is as yet unclear, but
their extensive colocalization with ubiquitin and p62 may suggest
a failed attempt by the cells to clear them and the toxic response
they may evoke (van Blitterswijk et al., 2012).
HUNTINGTON’S DISEASE
Huntington’s disease is the most common of the polyglutamine
(polyQ) disorders. While polyglutamine repeats are common
motifs that may facilitate protein-protein interactions, expansion
of these repeats is associated with at least nine different neu-
rodegenerative disorders (Ross, 1995; Orr, 2012). The threshold
length at which this expansion begins to elicit adverse effects
varies among these diseases, determined in part by the specific
protein context neighboring the repeat in the expanded protein
(Robertson et al., 2011). Expansion of the CAG repeat in exon
1 of the gene coding for the Huntingtin protein increases the
length of the polyglutamine domain (Myers et al., 1993; Snell
et al., 1993). The repeat length threshold for disease in HD is 38
or more repeats (Chong et al., 1997), with longer repeats causing
earlier onset and more severe disease. Symptoms of HD include
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progressive cognitive impairment, mood disorder and other psy-
chiatric symptoms, and highly disordered movement and motor
control, including abnormal movements such as chorea. These
progressive symptoms lead to mortality within 20 years of onset
(Walker, 2007). Histopathologically, HD is characterized by the
degeneration of striatal and cortical neurons and the presence of
intraneuronal, intranuclear aggregates, and dystrophic neurites.
Both of these latter features are marked by the presence of ubiq-
uitinated Huntingtin. These aggregates can be found in cortical
and striatal neurons, with some variance in cortical localization
related to the age of onset (DiFiglia et al., 1997).
The normal function of Huntingtin remains unknown.
Structural analyses and numerous other studies have led scientists
to propose several functions including intracellular protein traf-
ficking, modulation of gene transcription, and regulation of scaf-
folding proteins and NMDA receptors at the synapse (Cattaneo
et al., 2005; Parsons et al., 2013). NMDA receptors are improp-
erly localized to extra-synaptic sites in HD, and their signaling
at those sites contributes to the onset of symptoms in HD animal
models (Milnerwood et al., 2010; Gladding et al., 2012). This mis-
localization decreases synaptic NMDA receptor activation, which
has been shown to promote Huntingtin aggregation and neuronal
survival (Okamoto et al., 2009). Whether HD arises exclusively
from a toxic gain of function for mutant Huntingtin or from an
additional partial loss of normal Huntingtin function remains
unclear. In either case, ubiquitin plays a significant role in the
handling of normal and mutant Huntingtin protein (Figure 5).
The presence of ubiquitinated Huntingtin suggests a failure
of the UPS. Huntingtin is ubiquitinated (Kalchman et al., 1996),
but it has been proposed that the proteasome may be unable to
process expanded polyglutamine stretches, resulting instead in
the accumulation of peptide fragments containing polyglutamine
(Venkatraman et al., 2004). The fate of these peptide fragments is
unclear, but they may remain associated with the proteasome and
inhibit its function (Holmberg et al., 2004; Raspe et al., 2009).
Intriguingly, components of the UPS, including proteasomes,
have been identified within Huntingtin aggregates (Suhr et al.,
2001). This may represent deleterious proteasomal sequestration
in aggregates, even though aggregation ofmutant Huntingtinmay
itself be neuroprotective (Holmberg et al., 2004; Okamoto et al.,
2009). The idea that Huntingtin-induced pathology includes a
deficiency in UPS-mediated clearance is supported by the ben-
eficial effects observed following efforts to increase proteasomal
activity in models of HD (Seo et al., 2007). The upregulation of
UPS agents through the action of histone deacetylase inhibitors
may also improve the aggregation phenotype of HD model mice
(Jia et al., 2012).
The precise mechanisms by which Huntingtin is ubiquitinated
are not well understood. It is unclear whether, like TDP-43, ubiq-
uitination of Huntingtin includes both K48 and K63 linkages.
Most studies investigating this question have used models over-
expressing a fragment of Huntingtin with a polyQ expansion.
While such over-expression models induce aggregation and tox-
icity, their physiological relevance to the human disease state
remains an area of some debate. That said, in these model sys-
tems several components of the UPS contribute to the clearance of
mutant Huntingtin. HRD1, described above for its role in several
diseases, is implicated in the clearance of mutant Huntingtin.
The activity of HRD1 increases with Huntingtin polyQ expan-
sion length, suggesting that HRD1 regulation may not typically
handle normal, unexpanded Huntingtin (Yang et al., 2007). The
Tumor Necrosis Receptor Associated Factor 6 (TRAF6) is an E3-
ligase which binds to both unexpanded and mutant Huntingtin
and facilitates non-canonical ubiquitination through K6, K27,
and K29-linked chains (Zucchelli et al., 2011). The physiolog-
ical role of this modification is unclear, but it promotes the
aggregation of mutant Huntingtin without changing the local-
ization of the wild-type protein. Additionally, NUB1, described
above for its role in AD, works in conjunction with Cullin 3 to
facilitate the ubiquitination and clearance of mutant Huntingtin
(Lu et al., 2013).
Sumoylation also can regulate HD pathogenesis. Rhes, a
striatal protein which acts as a SUMO E3 ligase, binds
to mutant Huntingtin selectively and facilitates its sumoyla-
tion (Subramaniam et al., 2009). The sumoylation of mutant
Huntingtin decreases its aggregation; however, disaggregated,
sumoylated, mutant Huntingtin inhibits transcription, increases
cytotoxicity through Caspase-3, and may impair the induc-
tion of autophagy (Choo et al., 2004; Steffan et al., 2004;
Mealer et al., 2013).
Huntingtin is also reported to interact with the E2 enzyme
hE2-25k (Ube2K) (Kalchman et al., 1996). The presence of
Ube2k immunoreactivity in HD patient brains has been observed,
and the Huntingtin-Ube2k interaction promotes aggregation and
cytotoxicity in a manner that requires E2 catalytic function (de
Pril et al., 2007). Ube2k has been shown to interact with numer-
ous RING-finger E3 ligases (Lee et al., 2001). It is possible that
Ube25k cleaves the polyubiquitin chains attached to Huntingtin
to an extent that degradation is no longer signaled.
CONCLUSIONS: TOO BIG NOT TO FAIL
Befitting its extensive contributions to a wide range of cellular
processes, the systems of protein ubiquitination and ubiquitin-
dependent clearance are implicated at many levels of the most
common neurodegenerative disorders. Is this implied involve-
ment in disease incidental, or does dysregulated ubiquitination
and clearance represent an inevitable and common pathway for
the worsening of all neurodegenerative diseases? Because alter-
ations in ubiquitin-dependent gene transcription, translation,
control of protein quality and maturation, trafficking, mitochon-
drial turnover, and the handling of protein-protein interactions
are found in combination in neurodegenerative disease, it seems
likely that dysregulated ubiquitination will not remain limited to a
single ubiquitin-dependent process in a given disease. Instead, the
UPS and USS will be widely and progressively involved. To what
degree this involvement might begin the pathogenic cascade is
currently unclear. But based on the studies reviewed here, it seems
more likely that through a complex web of dysfunction in the UPS
and USS, involvement of these systems causes the pathogenicity
of aberrant proteins to diversify and flourish, affecting additional
systems and promoting the loss of synapses and cell death. As
questions remain about the mechanism by which the deposition
of abnormal protein progresses through regions of a diseased
brain, mounting evidence strongly supports the view that this
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FIGURE 5 | Ubiquitin-mediated handling of the pathologic
Huntingtin protein in Huntington’s disease. The Huntingtin protein
is improperly cleared from neurons in HD. Mutant Huntingtin can be
targeted for degradation in the ER by HRD1, and in the cytosol by
NUB1. However, this ubiquitination can be edited by UCHL1, inhibiting
the degradation of Huntingtin and promoting its aggregation in the
cytosol. Traf6 facilitates the non-canonical ubiquitination of Huntingtin
through the formation of K6, K27, and K29-linked polyubiquitin chains,
and these modifications selectively promote the aggregation of
mutant Huntingtin. Aggregates of mutant Huntingtin include
components of the UPS including proteasomes. Rhes promotes the
sumoylation of Huntingtin, which reduces its aggregation, but causes
sumoylated, mutant Huntingtin to interfere with other cellular
processes including gene transcription in the nucleus.
spread occurs within the context of weakening protein quality
control and ubiquitin-mediated pathways.
The UPS is not alone in its handling of unwanted or toxic
proteins. The autophagic system is the other major pathway by
which protein clearance is achieved. Autophagy especially regu-
lates the turnover of organelles and aggregated protein species,
and accordingly its role in neurodegenerative disease has been
extensively pursued. Upon failure of the proteasome, autophagic
mechanisms can be induced as a compensatory response to
UPS inhibition in numerous neurodegenerative diseases (Garcia-
Arencibia et al., 2010; Metcalf et al., 2012; Nixon, 2013). Further
activation of autophagic mechanisms through pharmacologic or
genetic manipulation has proven useful as a therapeutic interven-
tion in model systems (Hochfeld et al., 2013). It seems evident,
however, from the continued accumulation of ubiquitin-positive
proteins in neurodegeneration, that autophagic induction is not
sufficient to overcome this failure. Moreover, it is unclear what
effect sustained, heightened autophagy might have on already
weakened neurons.
The overlapping involvement of certain E3 ligases like HRD1,
NUB1, and CHIP not only speaks to their significance as key
regulators of proteostasis but also nominates them as important
targets for research. While knocking out CHIP has been shown to
exacerbate polyglutamine pathology (Williams et al., 2009), CHIP
over-expression can reduce proteotoxicity and the effects of cellu-
lar stress in numerous models (Miller et al., 2005; Adachi et al.,
2007; Lee et al., 2013). But CHIP induction without concurrent
upregulation of Hsp70 might worsen tau pathology, suggesting
that combinatorial approaches to therapy will be required.
In considering the specific goals and appropriate timing for
interventions intended to prevent or delay disease onset, it is
important to acknowledge that the loss of synapses can precede
neurodegeneration and is thought to underlie many of the earli-
est cognitive impairments in numerous diseases. As such, it may
represent a key step in the disease cascade and a critically impor-
tant target for therapies. Alternatively, synaptic connections may
simply be too costly for unhealthy neurons to properly main-
tain, and the loss of synaptic connections is, in effect, a response
intended to limit inappropriate and potentially dangerous synap-
tic signaling in disease states. In the latter case, this dauer-like state
is ultimately ineffective in staving off neurodegeneration, but may
slow the process. With respect to human disease, perhaps restor-
ing synapses could improve quality of life—regardless of whether
such a change ultimately lengthens or shortens the life-span of
affected neurons. For this reason, elucidation of the processes by
which ubiquitin governs synapse formation, maintenance, and
removal under normal conditions may prove invaluable.
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